At Seelos Therapeutics, we are focused on patients and their caregivers. We are committed to achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.
We are actively engaged and collaborating with patient and healthcare organizations.
We remain committed to providing access and information on our clinical trials for patients and their caregivers. Please click on the links below for more information. Emails are monitored by the respective study team and questions can be addressed by the team or the compound medical monitor.
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
For SLS-002 Team IN Ketamine clinical study queries, please contact: SLS002team@seelostx.com
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.
For SLS-005 Trehalose clinical study queries, please contact: SLS005team@seelostx.com
For additional information, please contact:
Healey Center for ALS at Massachusetts General Hospital
Phone: 833-425-8257 (HALT ALS)